A 72-year-old woman comes to the clinic reporting a 4-week history of worsening insomnia, … — USMLE Step 3

A 72-year-old woman comes to the clinic reporting a 4-week history of worsening insomnia, profound fatigue, and a 4.5-kg (10-lb) weight loss despite a normal appetite. Her past medical history is significant for hypertension and recurrent highly symptomatic atrial fibrillation. Her current medications include amiodarone, apixaban, and lisinopril. She has been taking amiodarone for the past three years with good control of her arrhythmias. Her blood pressure is 138/85 mm Hg and heart rate is 108/min and irregular. Physical examination reveals a fine tremor of the outstretched hands, warm and moist skin, and a normal-sized, non-tender thyroid gland without palpable nodules.

Laboratory results are as follows:

Test	Result	Reference Range
Thyroid-stimulating hormone (TSH)	$<0.01$ $\mu$ U/mL	$0.5$ - $5.0$ $\mu$ U/mL
Free thyroxine (T4)	$3.9$ ng/dL	$0.9$ - $2.4$ ng/dL
Free triiodothyronine (T3)	$5.1$ pg/mL	$2.0$ - $4.4$ pg/mL

Which of the following is the most appropriate next step in the evaluation to guide treatment for this patient's current condition?

Color Doppler ultrasonography of the thyroid glandAnswer
B
Radioactive iodine uptake scan
C
Immediate initiation of methimazole therapy
D
Immediate initiation of high-dose oral prednisone
E
Discontinuation of amiodarone and clinical observation

Answer

The most appropriate next step is to perform color Doppler ultrasonography of the thyroid gland to differentiate the type of amiodarone-induced thyrotoxicosis.

This patient is presenting with amiodarone-induced thyrotoxicosis (AIT), which has two distinct pathophysiologic mechanisms requiring completely different management strategies. Type 1 AIT is true hyperthyroidism resulting from the massive iodine load in amiodarone stimulating excess hormone production, typically occurring in patients with underlying autonomous thyroid tissue (e.g., multinodular goiter). Type 2 AIT is a destructive thyroiditis where amiodarone causes direct cytotoxicity, leading to the release of pre-formed thyroid hormone into the circulation. Differentiating the type is essential because Type 1 is managed with antithyroid drugs like methimazole, whereas Type 2 is managed with oral glucocorticoids. Because amiodarone saturates the body with iodine, standard radioactive iodine uptake (RAIU) scans will be universally suppressed and cannot differentiate between the two types. Therefore, color Doppler ultrasonography is the most appropriate next step in evaluation. Type 1 AIT typically shows normal or increased vascularity on Doppler flow, while Type 2 AIT demonstrates decreased or absent vascularity.

Step-by-Step Solution

Identify the adverse drug effect based on the patient's presentation and laboratory results.

The patient has clinical and laboratory evidence of primary hyperthyroidism (suppressed TSH, elevated T3 and T4) secondary to chronic amiodarone therapy.

Amiodarone contains a massive amount of iodine and has direct toxic effects on the thyroid gland, making amiodarone-induced thyrotoxicosis (AIT) a common complication.

Determine the need for differentiating the underlying mechanism before initiating therapy.

AIT presents as either Type 1 (hyperthyroidism driven by iodine load in an autonomous thyroid) or Type 2 (destructive thyroiditis).

Treatment must be tailored to the mechanism. Type 1 requires antithyroid drugs (methimazole), while Type 2 requires anti-inflammatory treatment (glucocorticoids).

Select the appropriate diagnostic modality.

Color Doppler ultrasonography of the thyroid gland is the test of choice.

Because radioactive iodine uptake is artificially suppressed in both types due to amiodarone's massive iodine load, ultrasonography is necessary to assess thyroid vascularity (increased in Type 1, decreased in Type 2) and guide the correct treatment pathway.

Key Concept

Patients with amiodarone-induced thyrotoxicosis must be evaluated with color Doppler ultrasonography to differentiate Type 1 (increased vascularity) from Type 2 (decreased vascularity) disease, as standard radioactive iodine scans are rendered non-diagnostic by amiodarone's high iodine content.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic